Bruker (NASDAQ:BRKR) Shares Up 9.2% - Time to Buy?

Key Points

• Bruker shares jumped 9.2% on Thursday, briefly touching $53.22, after trading below $49 in the prior close. Trading volume was below average, suggesting the move came on lighter-than-usual activity.
• Recent analyst action was mixed but tilted slightly positive, with Barclays raising its price target to $53 and several firms maintaining hold/buy views. Overall, the stock still carries an average Hold rating and a consensus price target of $50.54.
• Bruker’s latest earnings beat expectations, posting EPS of $0.31 vs. $0.23 expected and revenue of $823.4 million, above estimates. The company also announced a quarterly dividend of $0.05 per share, payable July 7.

Bruker Corporation (NASDAQ:BRKR - Get Free Report)'s share price shot up 9.2% during trading on Thursday . The stock traded as high as $53.22 and last traded at $53.1010. 1,276,187 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 2,308,142 shares. The stock had previously closed at $48.62.

Analyst Upgrades and Downgrades

Several brokerages have commented on BRKR. Barclays upped their price objective on Bruker from $45.00 to $53.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. TD Cowen increased their price target on Bruker from $43.00 to $45.00 and gave the stock a "hold" rating in a research report on Thursday, May 7th. Stifel Nicolaus set a $45.00 price target on Bruker in a research report on Friday, May 8th. Wall Street Zen raised Bruker from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. Finally, Weiss Ratings downgraded Bruker from a "sell (d+)" rating to a "sell (d)" rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $50.54.

Bruker Stock Up 9.8%

The business has a 50-day moving average price of $39.23 and a 200-day moving average price of $42.63. The firm has a market cap of $8.13 billion, a P/E ratio of -222.42, a P/E/G ratio of 2.81 and a beta of 1.12. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. During the same quarter last year, the company earned $0.47 earnings per share. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker's dividend payout ratio (DPR) is presently -83.33%.

Insiders Place Their Bets

In related news, VP Mark Munch sold 2,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the sale, the vice president owned 128,443 shares of the company's stock, valued at $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 27.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bruker

A number of institutional investors have recently added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd raised its stake in Bruker by 5.4% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company's stock valued at $702,256,000 after buying an additional 761,258 shares during the last quarter. State Street Corp raised its stake in Bruker by 2.5% in the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company's stock valued at $180,700,000 after buying an additional 91,706 shares during the last quarter. AQR Capital Management LLC raised its stake in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after buying an additional 1,850,215 shares during the last quarter. Sculptor Capital LP raised its stake in Bruker by 9.0% in the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock valued at $118,112,000 after buying an additional 270,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company's stock valued at $111,488,000 after buying an additional 2,289,269 shares during the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.